Hong Wang

Hong Wang

Auto-generated profile, based on publicly available information

Hong Wang

The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital Zhengzhou Henan Province China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2023 in Cancer Medicine
Verified
Journal Article
Open access
HWHong Wang
Hong Wang
YLYan‐Jie Li
Yan‐Jie Li
LLlei lin
lei lin
CLCheng‐Cheng Liu
Cheng‐Cheng Liu
WCWanqing Chen
Wanqing Chen
JHJie He
Jie He
Background: Colorectal cancer (CRC) is one of the most common cancers worldwide. Comprehensive data on the economic burden of CRC at a population‐level is critical in informing policymaking, but such data are currently limited in China.Methods: From a societal perspective, the economic burden of CRC in 2019 was estimated, including direct medical and nonmedical expenditure, disability, and premature‐death‐related indirect expenditure. Data on disease burden was taken from the GBD 2019 and analyzed using a prevalence‐based approach. The per‐person direct expenditure and work loss days were from a multicenter study; the premature‐death‐related expenditure was estimated using a human capital approach. Projections were conducted in different simulated scenarios. All expenditure data were in Chinese Yuan (CNY) and discounted to 2019.Results: In 2019, the estimated overall economic burden of CRC in China was CNY170.5 billion (0.189% of the local GDP). The direct expenditure was CNY106.4 billion (62.4% of the total economic burden), 91.4% of which was a direct medical expenditure. The indirect expenditure was CNY64.1 billion, of which 63.7% was related to premature death. The predicted burden would reach CNY560.0 billion in 2030 given constant trends for disease burden; however, it would be alternatively reduced to <CNY515.2 billion if the cancer prevention and control goals set by the United Nations and China for 2030 are achieved.Conclusions: The population‐level economic burden of CRC in China in 2019 seemed noteworthy, with the direct expenditure accounting for more than half. Without effectively reducing exposure to modifiable factors and expanding screening coverage, the burden would continue increasing.

11 December 2023 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
YLYin Liu
Yin Liu
JSJuan Su
Juan Su
XWXiaoyang Wang
Xiaoyang Wang
HXHuifang Xu
Huifang Xu
HWHong Wang
Hong Wang
SZShao-Kai Zhang
Shao-Kai Zhang
Background: The World Health Organization has proposed a worldwide target of eliminating hepatitis C virus (HCV) by 2030. A better understanding of HCV, testing behaviors, and associated factors in the general population is essential. Objective: This study aimed to assess HCV knowledge, self-reported HCV testing behavior, and willingness to undergo HCV screening in the general Chinese population. Methods: A cross-sectional online survey of the general Chinese population aged ≥15 years was conducted from November 2021 to May 2023. Participant characteristics were assessed based on their knowledge level and uptake of HCV testing. Participants ever having heard of HCV were recognized as being aware of HCV and asked additional HCV knowledge questions using a brief, validated 9-item scale. Participants with 0-3 points and who were unaware of HCV were categorized as having poor knowledge, and those with 4-6 points and 7 points were categorized as having fair and good knowledge, respectively. Participant uptake of HCV testing, testing results, reasons for undergoing or not undergoing HCV testing, and willingness to undergo HCV screening were collected through self-reports. Ordinal and binary logistic regression analyses were used to assess factors associated with the HCV knowledge level and the uptake of HCV testing, respectively. Results: A total of 1491 valid participants’ questionnaires were included. Of these, 714 (47.6%) participants were aware of HCV. The proportion of participants with poor, fair, and good HCV knowledge was 63.4% (945/1491), 9.3% (139/1491), and 27.3% (407/1491), respectively. A total of 465 (31.2%) participants reported ever undergoing HCV testing, and 4 (0.9%) were anti-HCV antibody positive. Most participants were tested for HCV following blood donation (353/465, 75.9%). The most common reasons for not undergoing HCV screening were a lack of HCV awareness (665/1026, 64.8%), followed by a low self-perceived risk of infection (176/1026, 17.2%). Of 1026 participants who had never undergone HCV testing, 937 (91.3%) were willing to undergo HCV screening if universal screening was provided at no cost. The HCV knowledge level was positively associated with the HCV testing rate. Participants who were less educated, lived in rural areas, resided in West China, and were currently alcohol drinkers had lower HCV knowledge and reduced odds of having undergone HCV testing. In contrast, participants with a blood donation history and a family history of hepatitis B virus or HCV infection had higher HCV knowledge and increased odds of prior testing. Participants aged ≥60 years had lower knowledge, and women had reduced odds of having undergone previous HCV testing. Conclusions: The general population of China has low HCV knowledge and testing rate. There is an urgent need for enhanced HCV awareness and scaled-up HCV screening and treatment. Individuals who are less well educated, reside in less-developed areas, currently drink alcohol, and are female should be prioritized for health education and interventions.

19 December 2024 in Journal of the National Cancer Center
Verified
Journal Article
Open access
QCQiong Chen
Qiong Chen
SLShuzheng Liu
Shuzheng Liu
YLYin Liu
Yin Liu
HLHongwei Liu
Hongwei Liu
HWHong Wang
Hong Wang
SZShaokai Zhang
Shaokai Zhang
To understand the current status and changing trends in the lifetime risk of residents in Henan Province, China to develop and die from cancer. Lifetime risk was estimated using the Adjusted for Multiple Primaries (AMP) method, incorporating cancer incidence, mortality, and all-cause mortality data from 55 cancer registries in Henan Province, China. Estimates were calculated overall and stratified by gender and area. The annual percent change (APC) in lifetime risk from 2010 to 2020, stratified by gender and cancer site, was estimated using a log-linear model. In 2020, the lifetime risk of developing and dying from cancer was 30.19 % (95 % CI: 29.63 %–30.76 %) and 23.62 % (95 % CI: 23.28 %–23.95 %), respectively. These estimates were higher in men, with values of 31.22 % (95 % CI: 30.59 %–31.85 %) for developing cancer and 26.73 % (95 % CI: 26.29 %–27.16 %) for dying from cancer, compared with women, who had values of 29.02 % (95 % CI: 28.12 %–29.91 %) and 20.08 % (95 % CI: 19.51 %–20.64 %), respectively. There were also geographical differences, with higher estimates in urban areas compared with rural areas. Residents had the highest lifetime risk of developing lung cancer, with a rate of 6.94 %, followed by breast cancer (4.14 %), stomach cancer (3.95 %), esophageal cancer (3.75 %), and liver cancer (2.86 %). Similarly, the highest lifetime risk of dying from cancer was observed for the following sites: lung (5.99 %), stomach (3.60 %), esophagus (3.39 %), liver (2.78 %), and colorectum (1.55 %). Overall, the lifetime risk of developing cancer increased, with an APC of 0.75 % (P < 0.05). Varying trends were observed across different cancer sites. There were gradual decreases in nasopharynx, esophagus, stomach, and liver cancers. Conversely, increasing trends were noted for most other sites, with the highest APCs observed in thyroid, prostate, lymphoma, kidney, and gallbladder cancers. The lifetime risks of developing and dying from cancer were 30.19 % and 23.62 %, respectively. Variations in cancer risk across different regions, genders, specific cancer sites, and over calendar years provide important information for cancer prevention and policy making in the population.

29 January 2024 in JMIR Preprints
Verified
Preprint
Open access
YWYu Jie Wu
Yu Jie Wu
YLYan Jie Li
Yan Jie Li
XWXin Wang
Xin Wang
XZXin Yi Zhou
Xin Yi Zhou
XYXin Xin Yan
Xin Xin Yan
JSJu Fang Shi
Ju Fang Shi
BACKGROUND Most studies evaluated disability-adjusted life years (DALYs) of colorectal cancer (CRC) based on a set of generic disability weights (DWs), while this study aimed to apply local CRC-stage-specific DWs to estimate CRC-DALYs value in Chinese populations and considered the influence of local screening coverage of CRC. OBJECTIVE This study aimed to estimate CRC-DALYs in 2017 and predict CRC-DALYs in 2030 by local DWs of the clinical stage(I-IV) from the Chinese study, and also took into account the influence of changes of local screening coverage of CRC. METHODS A prevalence-based model was constructed using data from various sources. Years lived with disability (YLDs) were mainly estimated using cumulative prevalence data (based on CRC incidence rates, population number, and survival rates), stage-specific proportions of CRC, and DWs of the local population. Years of life lost (YLLs) were calculated by the CRC mortality rates and standard life expectancies. Annual percent change (APC) from Joinpoint analyses was obtained to estimate CRC prevalence and mortality rates to 2030, and then to predict the DALYs for 2020, 2025, and 2030. Main assumptions were made for CRC screening coverage. Sensitivity analysis was used to assess the impact of population, DWs, and screening coverage on the results. RESULTS In Chinese populations in 2017, the estimated CRC-DALYs value was 4,303.3 thousand (11.8% for YLDs). If the CRC screening coverage in China (2.3%) remains unchanged, the overall DALYs in 2030 are predicted to increase by 37.2% (45.1% occurred to those aged 65+ years). More optimistically, the DALYs would then decrease by 0.7% in 2030 (from 5,902.5 thousand to 5,860.2 thousand) if the coverage rate can be increased to 25.0%. Sensitivity analysis showed that using local DWs would change the base-case values by ~5.7%. CONCLUSIONS Estimated CRC-DALYs in China using population-specific DWs were considerably lower (with a higher percentage of YLDs) than the GBD estimates (5,865.0 thousand, of 4.6% for YLDs), suggesting the impact of applying local parameters. Sustainable scale-up CRC screening needs to be in place to moderate the growth trend of CRC-DALYs in China.

12 March 2026 in Journal of Medical Screening
Verified
Journal Article
Closed access
XZXin-Yi Zhou
Xin-Yi Zhou
YLYan-Jie Li
Yan-Jie Li
HWHong Wang
Hong Wang
SCSen-Yao Cai
Sen-Yao Cai
XWXin Wang
Xin Wang
JSJufang Shi
Jufang Shi
Objective: Evidence is scarce about whether colorectal cancer screening can affect the quality of life of participants, particularly in terms of novel screening strategies in Eastern populations. Methods: From 2018 to 2021, the TARGET-C trial randomly allocated 19,373 participants to one of three screening strategies: (A) one-time colonoscopy; (B) annual faecal immunochemical test with positives referred for colonoscopy; and (C) annual risk-adapted screening with low-risk participants referred for faecal immunochemical test and high-risk participants referred for colonoscopy. Two rounds of follow-up after baseline screening were conducted over the 3-year period. Based on the TARGET-C, a EuroQol five-dimensional questionnaire-based quality of life survey was administrated to the participants, and utility scores and related changes were used as the main outcomes. Results: Taking by-strategy utility scores for participants before being screened at baseline as the comparators ( n = 2921), the changes in utility scores after baseline screening were −0.008 ( P < 0.050) for strategy A, 0.006 ( P < 0.050) for strategy B and 0.000 ( P > 0.050) for strategy C, and the overall difference in quality of life changes among the three strategies was significant ( P < 0.001). Taking the same comparators as above, the changes in utility scores for participants in the second round of follow-up ( n = 9201) were 0.011 ( P < 0.050), 0.011 ( P < 0.050) and 0.005 ( P < 0.050), respectively, and the overall difference was neither clinically meaningful nor statistically significant ( P = 0.113). Conclusions: None of the three colorectal cancer screening strategies had a major effect on the participants’ quality of life over the 3 years. Within one round of screening, incorporating risk-adapted screening and/or faecal immunochemical test might offset the quality of life impact from colonoscopy screening.

17 March 2026 in Journal of Applied Toxicology
Verified
Journal Article
Closed access
SWSiya Wu
Siya Wu
BWBoxiang Wang
Boxiang Wang
NZNing Zhang
Ning Zhang
CFChenxi Feng
Chenxi Feng
HWHong Wang
Hong Wang
SZShaokai Zhang
Shaokai Zhang